KFDA approves Clozaril as new use for reducing risk of suicidal behavior

The Korea Food and Drug Administration has recently approved a new use for the schizophrenia drug, Clozaril, for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.

Earlier, Clozaril was approved for treatment of schizophrenia in patients who do not respond other available therapies.

Suicidal behavior refers to actions by a patient...